The antiapoptotic effect of fibroblast growth factor-2 is mediated through nuclear factor-kappaB activation induced via interaction between Akt and IkappaB kinase-beta in breast cancer cells
Fibroblast growth factor-2 (FGF-2) is known for its mitogenic and motogenic effects on breast cancer cells. Here, we demonstrate that FGF-2 is also a potent stimulator of breast cancer cell survival, as it counteracts the apoptotic activity of the C2 ceramide analogue and various chemotherapeutic agents (5-fluorouracil, camptothecin, etoposide) in MCF-7, T47-D and BT-20 cells. The use of pharmacological inhibitors (PD98059, wortmannin, LY294002, SN50) and transfection with negative dominants (IkappaBm, p110(PI3K (phosphoinositide 3-kinase))*DeltaK, AktND) or small interfering RNA targeted against Akt indicated that PI3K/Akt and nuclear factor-kappaB (NF-kappaB), but not p42/p44 MAP-kinases, were required to stimulate FGF-2 antiapoptotic activity. The activation of NF-kappaB was dependent on PI3K/Akt, and using a combination of approaches based on immunoprecipitation, Western blotting and proteomics (two-dimensional electrophoresis and mass spectrometry), we identified the beta form of IkappaB kinase (IKKbeta) as a target of Akt signaling. The selective disruption of IKKbeta using small interfering RNA induced a potent inhibition of Akt-mediated activation of NF-kappaB and cell survival, indicating the functional involvement of IKKbeta in FGF-2 antiapoptotic signaling. Together, these results demonstrate Akt/IKKbeta interaction in NF-kappaB pathways, thereby emphasizing the potential of these proteins as therapeutic targets in breast cancer.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2005 |
|---|---|
| Erschienen: |
2005 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Oncogene - 24(2005), 35 vom: 18. Aug., Seite 5482-91 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vandermoere, Franck [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 15.09.2005 Date Revised 03.12.2021 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM155041622 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM155041622 | ||
| 003 | DE-627 | ||
| 005 | 20231223071256.0 | ||
| 007 | tu | ||
| 008 | 231223s2005 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0517.xml |
| 035 | |a (DE-627)NLM155041622 | ||
| 035 | |a (NLM)15856005 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vandermoere, Franck |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The antiapoptotic effect of fibroblast growth factor-2 is mediated through nuclear factor-kappaB activation induced via interaction between Akt and IkappaB kinase-beta in breast cancer cells |
| 264 | 1 | |c 2005 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 15.09.2005 | ||
| 500 | |a Date Revised 03.12.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Fibroblast growth factor-2 (FGF-2) is known for its mitogenic and motogenic effects on breast cancer cells. Here, we demonstrate that FGF-2 is also a potent stimulator of breast cancer cell survival, as it counteracts the apoptotic activity of the C2 ceramide analogue and various chemotherapeutic agents (5-fluorouracil, camptothecin, etoposide) in MCF-7, T47-D and BT-20 cells. The use of pharmacological inhibitors (PD98059, wortmannin, LY294002, SN50) and transfection with negative dominants (IkappaBm, p110(PI3K (phosphoinositide 3-kinase))*DeltaK, AktND) or small interfering RNA targeted against Akt indicated that PI3K/Akt and nuclear factor-kappaB (NF-kappaB), but not p42/p44 MAP-kinases, were required to stimulate FGF-2 antiapoptotic activity. The activation of NF-kappaB was dependent on PI3K/Akt, and using a combination of approaches based on immunoprecipitation, Western blotting and proteomics (two-dimensional electrophoresis and mass spectrometry), we identified the beta form of IkappaB kinase (IKKbeta) as a target of Akt signaling. The selective disruption of IKKbeta using small interfering RNA induced a potent inhibition of Akt-mediated activation of NF-kappaB and cell survival, indicating the functional involvement of IKKbeta in FGF-2 antiapoptotic signaling. Together, these results demonstrate Akt/IKKbeta interaction in NF-kappaB pathways, thereby emphasizing the potential of these proteins as therapeutic targets in breast cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a NF-kappa B |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins |2 NLM | |
| 650 | 7 | |a Fibroblast Growth Factor 2 |2 NLM | |
| 650 | 7 | |a 103107-01-3 |2 NLM | |
| 650 | 7 | |a AKT1 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a Protein Serine-Threonine Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins c-akt |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a CHUK protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.11.10 |2 NLM | |
| 650 | 7 | |a I-kappa B Kinase |2 NLM | |
| 650 | 7 | |a EC 2.7.11.10 |2 NLM | |
| 650 | 7 | |a IKBKB protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.11.10 |2 NLM | |
| 650 | 7 | |a IKBKE protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.11.10 |2 NLM | |
| 700 | 1 | |a El Yazidi-Belkoura, Ikram |e verfasserin |4 aut | |
| 700 | 1 | |a Adriaenssens, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Lemoine, Jérôme |e verfasserin |4 aut | |
| 700 | 1 | |a Hondermarck, Hubert |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncogene |d 1990 |g 24(2005), 35 vom: 18. Aug., Seite 5482-91 |w (DE-627)NLM012595683 |x 1476-5594 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2005 |g number:35 |g day:18 |g month:08 |g pages:5482-91 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2005 |e 35 |b 18 |c 08 |h 5482-91 | ||